

1 **Mapping the tumor stress network reveals dynamic shifts in the stromal oxidative stress**  
2 **response**

3 Chen Lior<sup>1</sup>, Debra Barki<sup>1</sup>, Christine A Iacobuzio-Donahue<sup>2</sup>, David Kelsen<sup>3</sup> and Ruth Scherz-  
4 Shouval<sup>1#</sup>

5 <sup>1</sup>Department of Biomolecular Sciences, The Weizmann Institute of Science, Rehovot, Israel

6 <sup>2</sup>Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA

7 <sup>3</sup>Gastrointestinal Oncology Service, Memorial Sloan Kettering Cancer Center, Weill Cornell  
8 Medical College, New York, NY, USA.

9 <sup>#</sup> Corresponding author: [ruth.shouval@weizmann.ac.il](mailto:ruth.shouval@weizmann.ac.il)

10

11 **Abstract**

12 The tumor microenvironment (TME) is a challenging environment where cells must cope with  
13 stressful conditions such as fluctuating pH levels, hypoxia, and free radicals. In response, stress  
14 pathways are activated, which can both promote and inhibit tumorigenesis. In this study, we set  
15 out to characterize the stress response landscape across four carcinomas: breast, pancreas, ovary,  
16 and prostate tumors, focusing on five pathways: Heat shock response, oxidative stress response,  
17 unfolded protein response, hypoxia stress response, and DNA damage response. Using a  
18 combination of experimental and computational methods, we create an atlas of the stress response  
19 landscape across various types of carcinomas. We find that stress responses are heterogeneously  
20 activated in the TME, and highly activated near cancer cells. Focusing on the non-immune stroma  
21 we find, across tumor types, that NRF2 and the oxidative stress response are distinctly activated  
22 in immune-regulatory cancer-associated fibroblasts and in a unique subset of cancer associated  
23 pericytes. Our study thus provides an interactome of stress responses in cancer, offering new ways  
24 to intersect survival pathways within the tumor, and advance cancer therapy.

## 25      **Introduction**

26      Cancer development and progression is a complex process involving not only malignant cells but  
27      also the surrounding tumor microenvironment (TME), comprising various non-malignant cells  
28      such as fibroblasts, pericytes, and immune cells. These cells face a stressful environment due to  
29      nutrient scarcity, hypoxia, fluctuating pH levels, and demands for rapid protein translation,  
30      necessitating the activation of survival pathways (Akman, 2021; Seebacher et al, 2021; Leprivier  
31      et al, 2015).

32      Within the tumor microenvironment, cancer-associated fibroblasts (CAFs) and pericytes are  
33      among the most abundant cell types in various carcinomas, and they contribute significantly to  
34      cancer progression (Ping et al, 2021; Sun et al, 2021). CAFs, a heterogeneous population  
35      originating from various sources, are generally divided into three – myofibroblastic CAFs  
36      (myCAFs), immune-regulatory CAFs (iCAFs), and antigen-presenting CAFs (apCAFs)(Sahai *et*  
37      *al*, 2020; Ping *et al*, 2021; Santi *et al*, 2018; Ganguly *et al*, 2020; Liu *et al*, 2019; Chen *et al*, 2021b). They  
38      interact with other cells of the TME, such as immune cells, facilitating a pro-tumorigenic  
39      environment (Liu *et al*, 2019; Lavie *et al*, 2022; Elyada *et al*, 2019; Arpinati & Scherz-Shouval, 2023;  
40      Mun *et al*, 2022). Pericytes, mural cells of blood vessels, are involved in tumor angiogenesis and  
41      metastasis, regulating vascular stability, and enhancing tumor cell intravasation when  
42      dysfunctional (Armulik *et al*, 2011; Sun *et al*, 2021). Although these cells evidently play a significant  
43      role in tumor progression, our understanding of their transformation into cancer-associated states  
44      and their mechanisms of influence remains a topic of active research (Ping *et al*, 2021; Ganguly *et*  
45      *al*, 2020; Liu *et al*, 2019; Chen *et al*, 2021b; Kharashvili *et al*, 2014).

46      Cellular stress responses, including the unfolded protein response (UPR) (Hetz, 2012), heat shock  
47      response (HSR) (Richter *et al*, 2010), oxidative stress response, (OSR) (Sies & Jones, 2020) hypoxia  
48      stress response, (HySR) (Semenza, 2014), and the DNA damage response (DDR) (Lord &  
49      Ashworth, 2012), help maintain cellular homeostasis and survival under adverse conditions. In the  
50      context of cancer, these pathways have a dual role: they can promote survival and thus facilitate  
51      tumorigenesis, however chronic activation of them can lead to cell death, potentially inhibiting  
52      tumor growth (Siwecka *et al*, 2019). For example, both the HSR and the UPR can promote cancer  
53      cell survival by stabilizing protein folding and reducing protein aggregation (Li *et al*, 2011; Madden

54 *et al*, 2019; Cyran & Zhitkovich, 2022); hypoxic conditions were shown to be beneficial for the tumor  
55 by promoting vascularization and angiogenesis (Li *et al*, 2021; Krock *et al*, 2011; Sebestyén *et al*,  
56 2021), and mutations in DNA damage response genes, such as *BRCA1* and *BRCA2*, can result in  
57 genome instability and an increased risk of developing breast and ovarian cancers (Roy *et al*, 2012).  
58 Understanding these cellular stress responses within the TME is crucial for developing novel  
59 cancer therapies, highlighting the need for further research into the specific mechanisms and  
60 signaling pathways involved, their interactions, and their potential as therapeutic targets.  
61 In recent years there have been numerous studies exploring the potential roles of stress responses  
62 in various cellular components of the TME (Varone *et al*, 2021; Grunberg *et al*, 2020; Zhang *et al*,  
63 2013; Ramirez *et al*, 2020; Nguyen *et al*, 2018; Chen & Cubillos-Ruiz, 2021; Miles *et al*, 2019). Work by  
64 us and others described the importance of different stress responses in CAFs, and highlighted non-  
65 cell-autonomous roles for stress responses (Martinez-Outschoorn *et al*, 2010; Verginadis *et al*, 2022;  
66 Matsuzaki *et al*, 2015; Chan *et al*, 2017; Scherz-Shouval *et al*, 2014; Grunberg *et al*, 2021; Levi-Galibov  
67 *et al*, 2020; Shaashua *et al*, 2022). However, these studies have largely focused on individual stress  
68 responses. We lack a comprehensive description of the stress network. Given the diversity and  
69 intercommunication among cells within the TME, a nuanced, cell-specific understanding of how  
70 stress responses influence each cellular compartment and interact with each other is pivotal.  
71 In this study, we took a holistic approach and examined the network of stress responses in the  
72 tumor and its microenvironment. We utilized multiplexed immunofluorescence (MxIF) staining  
73 of human patient samples to characterize activation patterns of stress responses across carcinomas  
74 in four different organs - pancreas, breast, ovary, and prostate. We found a gradient of activation,  
75 whereby stromal cells located closer to the cancer cells exhibit higher stress response activation  
76 levels. Analysis of patient-derived single-cell RNA-sequencing (scRNA-seq) data allowed us to  
77 create a cell- and organ-specific atlas of the stress response landscape across various types of  
78 carcinomas. Through our analysis, we discerned distinct subpopulations of fibroblasts and  
79 pericytes that exhibit a clear association with cellular stress, in particular oxidative stress,  
80 orchestrated by the transcription factor NRF2. This comprehensive map and the identified  
81 molecular interactions pave the way to elucidate the contribution of stress responses in the tumor

82 microenvironment in a cell-specific manner. Moreover, it offers insights into how the stress  
83 response landscape might influence tumor progression and disease outcome.

84


85

## 86 **Results**

### 87 **Stress responses are heterogeneously activated in the stroma, and their activation increases 88 with proximity to cancer cells.**

89 To map the stress response network in the TME, we monitored the activation status in human  
90 tumors of transcription factors driving three major stress response pathways. We stained human  
91 tumor microarrays (TMAs) derived from four tumor types – breast, pancreas, ovary, and prostate  
92 – with antibodies for three stress transcription factors (TFs): NRF2 (Nuclear factor erythroid 2-  
93 related factor 2), a key factor of the oxidative stress response (OSR); ATF4 (Activating  
94 transcription factor 4), a master regulator of the unfolded protein stress response (UPR) and the  
95 integrated stress response; and HSF1 (Heat shock factor 1), which orchestrates the heat shock  
96 stress response (HSR) (Figure 1A). These TFs translocate to the nucleus upon activation and  
97 therefore their localization can be used as a proxy to monitor activation (Shaashua *et al*, 2022). Non-  
98 immune stromal cells were identified by negative staining for CD45 (immune cells) and CK  
99 (epithelial cells). Across all tumors, stress TFs were more strongly activated in cancer cells  
100 compared to non-malignant cells in the TME, as expected(Chen & Xie, 2018). Nevertheless, we  
101 observed marked activation of stress TFs in stromal cells, which appeared to be spatially  
102 heterogeneous (Figure 1A). To assess this spatial diversity, we calculated the distance between  
103 each non-immune stromal cell and its nearest cancer cell and examined whether this distance  
104 differs between stressed and unstressed cells (defined as cells that stained positively for one of the  
105 stress TFs, see Methods). We found that, across tumor types, stressed stromal cells are localized  
106 significantly closer to the cancer cells compared to unstressed stromal cells (Figure 1B). Analyzing  
107 each stress pathway separately, we observed a negative correlation between the staining intensity  
108 of each stress marker and the distance of the stromal cell to the nearest cancer cell (Figure 1C).  
109 This was true across all tumor types, yet it was most pronounced in ovarian tumors and least  
110 evident in pancreatic tumors, suggesting not only that the spatial heterogeneity of stress responses  
111 varies among tumor types but also that cancer cells might transfer, confer, or induce stress to the  
112 stroma.

Lior et al, Figure 1




**Figure 1. Stromal stress response activation increases with proximity to cancer cells.** Formalin-fixed paraffin-embedded (FFPE) tumor microarrays (TMAs) of breast (N = 57), pancreas (N = 71), ovary (N = 102) and prostate (N = 43) cancer patients were stained by MxIF for the indicated proteins. DAPI was used to stain nuclei. **(A)** Representative images are shown. Scale bar = 50  $\mu$ m. **(B)** Images were analyzed using QuPath software, CD45 $^-$  CK $^-$  cells were defined as non-immune stromal cells, and stratified to stressed and unstressed cells based on staining for either NRF2, HSF1, or ATF4. The distance of each non-immune stromal cell to its nearest cancer cell was calculated and averaged. **(C)** For each patient, the Pearson correlation coefficient between the intensity of the indicated protein of non-immune stromal cells and the distance to the nearest cancer cell was calculated. P-Values were calculated using the Student t-test (**B**-paired t-test, **C**-one sample t-test ( $\mu=0$ )).

114 **Transcriptomic analysis uncovers universal and organ-specific non-cell autonomous stress**  
115 **response activation patterns.**

116 To gain a better understanding of the stress response landscape in the TME, we evaluated the  
117 transcriptional patterns of the different stress responses in the TME using publicly available  
118 scRNA-seq data of the four tumor types (breast, pancreas, ovary, prostate) (Pal *et al*, 2021; Wu *et*  
119 *al*, 2021; Chen *et al*, 2021a; Werba *et al*, 2023; Steele *et al*, 2020; Geistlinger *et al*, 2021; Zhang *et al*, 2022;  
120 Olbrecht *et al*, 2021; Peng *et al*, 2019) (Figure 2A-D). To the three stress responses evaluated by  
121 immunostaining (OSR, HSR and UPR), we added the cellular response to hypoxia (HySR) and the  
122 DNA damage response (DDR). We generated a score for each stress response based on the average  
123 expression levels of a signature of target genes (50-250 genes each, see Methods, Supplementary  
124 Table 1). For each patient, we determined the mean expression for each of the five stress scores  
125 and then compared the scores across different cell types (Figure 2E-I; Supplementary Figure 1A-  
126 E). We found distinct patterns of expression in the different cell types, which were largely shared  
127 across tumor types. OSR scores were highest in epithelial, myeloid, pericytes and fibroblasts  
128 (Figure 2E; Supplementary Figure 1A), while the hypoxia stress response was highest in  
129 endothelial cells in breast, pancreas, and prostate tumors, and was among the highest in the  
130 endothelial cells of ovarian tumors (Figure 2F; Supplementary Figure 1B). HSR scores were  
131 divergent in their distribution across cell types in the different tumors (Figure 2G; Supplementary  
132 Figure 1C), and B cells expressed high UPR scores in all tumors, potentially due to the protein  
133 folding stress associated with the requirement to translate and sustain a high level of antibodies  
134 (Jiang *et al*, 2021) (Figure 2H; Supplementary Figure 1D). T, B, and myeloid cells expressed high  
135 DNA damage response scores in all tumors (Figure 2I; Supplementary Figure 1E). To assess not  
136 only the individual stress responses but their potential co-regulation, we calculated correlations  
137 between the stress scores of each cell type across patients (Figure 3A-D). While different organs  
138 have different stress networks, we observe some shared characteristics: In breast, pancreas, and  
139 ovarian tumors there is a strong co-regulation of non-immune-stromal HySR - (fibroblasts,  
140 endothelial cells and/or pericytes; Figure 3A-C), and the DDR is co-regulated in different immune  
141 cell types in breast, pancreas, and prostate tumors, indicating that these stresses are experienced  
142 similarly in those cell types. The HSR appears to be the most global stress response in prostate  
143 tumors, while in pancreatic tumors it appears to be the DDR, and in ovarian tumors the UPR,  
144 indicated by a co-regulation pattern across most cell types (Figure 3A-D). In breast tumors, both


145 HSR and OSR are strongly correlated in the non-immune stroma. Taken together, the imaging and  
 146 scRNA-seq analysis suggest an inter-cellular communication network of stress responses in the  
 147 TME, with global as well as organ-specific characteristics.

Lior et al, Figure 2



**Figure 2. scRNA-seq data analysis uncovers shared and unique stress response patterns across organs.** scRNA-seq data from human breast, pancreas, ovary, and prostate tumors was reanalyzed using the Seurat R toolkit. **(A-D)** UMAP plots of 265,034 cells from 51 breast cancer patients (Pal *et al*, 2021; Wu *et al*, 2021) **(A)**; 199,938 cells from 59 pancreatic cancer patients (Werba *et al*, 2023; Steele *et al*, 2020; Peng *et al*, 2019) **(B)**; 84,369 cells from 20 ovarian cancer patients (Geistlinger *et al*, 2021; Zhang *et al*, 2022; Olbrecht *et al*, 2021) **(C)**; and 32,823 cells from 13 prostate cancer patients (Chen *et al*, 2021a) **(D)**. UMAPs are colored by cell type, defined by differential gene expression and canonical cell type markers. **(E-I)** Quantification of stress scores per cell type for each tumor across patients- **(E)** OSR; **(F)** HySR; **(G)** HSR; **(H)** UPR; and **(I)** DDR. Different letters denote significant differences in stress scores as determined by ANOVA followed by Tukey's HSD test. Groups with the same letter are not significantly different from each other.

Lior *et al*, Figure 3



**Figure 3. Correlation analysis of stress signatures reveals coordinated activation of the HSR in prostate tumors, the DDR in pancreatic tumors and the UPR in ovarian tumors. (A-D)** Correlation matrix of stress scores of different cell types across patients calculated from the scRNA-seq datasets listed in Figure 2. Per-patient average scores were quantified, and Pearson coefficients of all possible pairs were calculated. Outlier patients were removed to avoid bias. Color bars indicate the stress or cell type.

150 **Specific subsets of CAFs and pericytes exhibit increased stress response activation.**

151 The finding that stromal cells located close to cancer cells tend to exhibit higher stress scores  
152 prompted us to test the effect of spatial positioning on the transcriptional stress signatures. To  
153 incorporate this dimension, we analyzed publicly available human cancer spatial transcriptomics  
154 data from breast, ovarian and prostate tumors (see Methods; Supplementary Figure 2A-E). We  
155 defined cell types and stress patterns using scRNA-seq data (Pal *et al*, 2021; Wu *et al*, 2021; Chen  
156 *et al*, 2021a; Geistlinger *et al*, 2021; Zhang *et al*, 2022; Olbrecht *et al*, 2021) and he stress signatures  
157 we generated, respectively. In breast and ovarian tumor slides, epithelial cells predominated,  
158 followed closely by CAFs. Roughly half of the cells in these samples belonged to the immune  
159 compartment (Supplementary Figure 2C-D). In contrast, prostate tumor slides were primarily  
160 composed of epithelial cells, CAFs, and pericytes, with a minimal presence of immune cells  
161 (Supplementary Figure 2E). We then asked which cell types are enriched within regions expressing  
162 high stress activation signatures. We found, in breast and ovarian tumors, that regions with high  
163 HSR, UPR and DDR expression were enriched with cancer/epithelial cells; while regions with  
164 high OSR and HySR were enriched with stromal cells, specifically CAFs (Supplementary Figure  
165 2C-E). These results are consistent with the stress expression patterns we witnessed in the scRNA-  
166 seq analysis (Figure 2E-I, Supplementary Figure 1A-E), and highlight the differential stress  
167 activation between cancer and stromal cells in the TME.


168 While stress responses in the immune-TME were extensively studied, our understanding of the  
169 global stromal stress network is limited. Major players in the stromal microenvironment are CAFs.  
170 Recently, pericytes were also shown to contribute to the stromal TME, by transitioning into CAF-  
171 like protumorigenic cells (Sun *et al*, 2021).

172 CAFs were shown to divide into 3 subpopulations: myofibroblastic CAFs (myCAFs), immune-  
173 regulatory CAFs (iCAF), and antigen-presenting CAFs (apCAF) (Lavie *et al*, 2022). The  
174 heterogeneity of pericytes is less studied, but recent studies suggest the existence of two main  
175 subpopulations of pericytes in the TME which differ functionally (Li *et al*, 2023; Lyle *et al*, 2016).  
176 Indeed, when we re-analyzed the transcriptional landscape of fibroblasts and pericytes from the  
177 above-mentioned datasets, we found the three CAF subpopulations (Figure 4A-D; Supplementary  
178 Figure 3A-E; Supplementary Table 2). In ovarian tumors we also identified a cluster of mesothelial  
179 cells. Ovarian mesothelial cells cover the peritoneal cavity and are involved in ovarian cancer

180 progression (Mogi *et al*, 2021). In the prostate cancer dataset, we observed a limited number of  
181 CAFs. Given that multiple studies have highlighted the presence and role of fibroblasts in prostate  
182 tumors, this could be attributed to a technical variation (Bedeschi *et al*, 2023; Bonollo *et al*, 2020).  
183 We also identified two distinct cancer-associated pericyte subpopulations, which we termed  
184 matriPer and musclePer, based on enriched pathway analysis (Figure 4A-D; Supplementary Figure  
185 3F; Supplementary Table 3). Top upregulated pathways for matriPer were associated with the  
186 matrisome and wound healing processes, while musclePer showed an enrichment in muscle  
187 contraction pathways, indicating a distinct role for each of the pericyte subpopulations in the TME.  
188 These results align with a recent study that identified similar pericyte subsets in colorectal tumors  
189 (Li *et al*, 2023). For each fibroblast and pericyte subpopulation, we defined a unique gene signature  
190 that is shared across all four organs using differential gene expression analysis (see Methods;  
191 Supplementary Table 2, Supplementary Figure 3A-E).

192 Next, to assess the stress responses activation of these cells, we projected the stress scores on the  
193 fibroblast and pericyte UMAPs (Figure 4E-I). We calculated the average scores per patient and  
194 compared them among the subpopulations of fibroblasts (Supplementary Figure 4A-E) and  
195 pericytes (Supplementary Figure 4F-J). Due to the low number of fibroblasts in the prostate  
196 dataset, we did not analyze the fibroblast subpopulations in this tumor type. Additionally, due to  
197 their vast abundance and dominant presence across the different tumors, we focused our  
198 downstream analysis on the iCAF, myCAF, MatriPer and MusclePer subpopulations. We found  
199 that the OSR score is higher in iCAFs compared to myCAFs in all three organs (Figure 4E,  
200 Supplementary Figure 4A). HySR scores were higher in breast and pancreas tumor iCAFs (Figure  
201 4F, Supplementary Figure 4B), while DDR scores were elevated in breast iCAFs, as well (Figure  
202 4I, Supplementary Figure 4E). Additionally, musclePer had higher OSR in all tumors, and higher  
203 HSR scores in breast, pancreas, and ovary tumors (Figure 4E,G; Supplementary Figure 4F,H).  
204 These results identify two subpopulations of the non-immune stroma – iCAF and musclePer – as  
205 stress-associated and can indicate specific roles for them in tumor progression, while  
206 phenotypically distinguishing them from other fibroblasts and pericytes.

Lior et al, Figure 4



**Figure 4. The hypoxia and oxidative stress responses are differentially activated across subpopulations of the non-immune tumor stroma. (A-D)** UMAP plots of 20,754 fibroblasts and pericytes from 51 breast cancer patients (A); 14,516 fibroblasts and pericytes from 57 pancreas cancer patients (B); 10,762 fibroblasts and pericytes from 20 ovarian cancer patients (C); and 1,697 fibroblasts and pericytes from 12 prostate cancer patients (D). UMAPs are colored by cell type, defined by the gene signatures we defined (Supplementary Table 2). The scRNA-seq data originates from the same datasets highlighted in Figure 2 (E-I) Projection of the five stress signatures scores (E) OSR; (F) HySR; (G) HSR; (H) UPR; and (I) DDR.


208 **NRF2 and the oxidative stress response are activated in iCAFs.**

209 To further investigate the interplay between oxidative stress and stromal heterogeneity, we  
210 analyzed the correlations between stress and cell type signatures at the single cell level (Figure  
211 5A-B; Supplementary Figure 5A-B). The iCAF and OSR signatures showed a positive correlation  
212 across all tumor types (Figure 5A), while the myCAF signature did not correlate positively with  
213 any stress response and was in fact negatively correlated with the OSR signature (Supplementary  
214 Figure 5A). In pericytes, the musclePer subpopulation showed a positive correlation with the OSR  
215 signatures (Figure 5B), while the matriPer subpopulation showed no positive correlations with any  
216 of the stress responses (Supplementary Figure 5B).

217 To test whether these findings translate to the protein level, we stained human tissue microarrays  
218 of different tumors for markers of the three main CAF subpopulations (CLU, iCAF;  $\alpha$ SMA,  
219 myCAF; MHC-II, apCAF) (Lavie *et al*, 2022) and for NRF2, the main regulator of the oxidative  
220 stress response, and then quantified and calculated the correlation between the intensities of NRF2  
221 and the three CAF markers at single cell level (Figure 5C). We found that NRF2 staining positively  
222 correlated with CLU staining in the non-immune stroma of breast, pancreas, ovary, and prostate  
223 tumors. Moreover, we found that the NRF2-CLU correlation was the highest compared to all other  
224 CAF markers (Figure 5D), suggesting that the more the OSR is activated in a cell, the higher the  
225 likelihood that it is an iCAF. These findings support the conclusion that iCAFs show a stronger  
226 OSR and point to a mechanistic role for NRF2 in the regulation of the iCAF phenotype.

227 To test this hypothesis in an independent dataset, we analyzed patient data from the TCGA  
228 database of breast, pancreas, and ovary tumors. We aimed to assess the correlation between the  
229 different stress responses and the cellular composition of the tumor. We implemented the  
230 CIBERSORTx(Newman *et al*, 2015) algorithm to estimate the fractions of the different cell types in  
231 the tumors. We then ranked the patients from lowest to highest stress score (Figure 6A-E;  
232 Supplementary Figure 5C-L). We found that across all 3 tumor types the HySR appeared to be  
233 inversely correlated with the number of epithelial cells, and the OSR shows the same behavior in  
234 breast and ovarian tumors (Figure 6A,B; Supplementary Figure 5C-D,H-I; dark blue). The UPR,  
235 on the other hand, showed an opposite trend - the relative number of epithelial cells increased as  
236 the UPR score increased in breast cancer (Figure 6D). Additionally, for both OSR and HySR, the  
237 iCAF population (dark red) seemed to increase as the stress score increased and the epithelial cells  
238 decreased in breast and pancreas tumors (Figure 6A,B; Supplementary Figure 5C-D). These results

Lior et al, Figure 5




**Figure 5. NRF2 and the oxidative stress response are associated with iCAF signature. (A-B)**

Pearson correlation coefficients between stress and cell type scores calculated from the scRNA-seq data described in Figure 4. **A** - iCAFs; **B** - musclePer. P-Values were calculated using one sample t-test ( $\mu=0$ ). **(C-D)** Formalin-fixed paraffin-embedded (FFPE) tumor microarrays (TMAs) of breast ( $N = 114$ ), pancreas ( $N = 125$ ), ovary ( $N = 93$ ), and prostate ( $N = 104$ ) cancer patients were stained by MxIF and analyzed using QuPath software,  $CD45^- CK^-$  cells were defined as non-immune stromal cells. Representative images are shown **(C)**. Scale bar = 40 $\mu$ M. For each patient Pearson correlation coefficients between the staining intensities of NRF2 and the different CAF markers CLU,  $\alpha$ SMA and MHC-II were calculated **(D)**. P-Values were calculated using one-way ANOVA, followed by Tukey's multiple comparisons test.

240 support our claim that oxidative stress is associated with the iCAF phenotype.  
241 Supported by our finding that NRF2 and the OSR are high in iCAFs, and since it was suggested  
242 that normal fibroblasts likely give rise to iCAFs (Houthuijzen *et al*, 2023), we hypothesized that  
243 NRF2 either regulates the transition of normal fibroblasts to iCAF, the transition from iCAFs to  
244 myCAFs, or both. To test this hypothesis, we performed trajectory analysis of two of the scRNA-  
245 seq datasets we analyzed, which also contained normal samples of breast and pancreatic tissues  
246 (Pal *et al*, 2021; Peng *et al*, 2019)(Figure 6F-J,K-O). In both breast and pancreas, pseudotime analysis  
247 revealed a gradual transition from normal fibroblasts to iCAFs and then to myCAFs (Figure  
248 6H,M). The OSR gene signature follows an opposite trajectory – OSR is silenced as fibroblasts  
249 transition from normal fibroblasts to myCAFs (Figure 4I,N). Averaging the OSR scores per patient  
250 revealed a gradual decrease of the OSR score in the normal-iCAF-myCAF trajectory (Figure 4J,O).  
251 The pancreatic HySR was the only other stress response to show this pattern of expression  
252 (Supplementary Figure 5M-N). These results suggest a role for NRF2 and the oxidative stress  
253 response in the transition from normal fibroblasts to iCAFs and from iCAFs to myCAFs.  
254 To assess the clinical implications of our findings, we investigated whether the levels of OSR and  
255 the relative abundance of iCAFs within the tumor were associated with patient survival. A cohort  
256 of 1053 breast cancer patients from the METABRIC dataset (Curtis *et al*, 2012) was utilized for this  
257 purpose. We used CIBERSORTx (Newman *et al*, 2015) to profile the cellular composition of the  
258 tumors. Our analysis revealed that patients with both low iCAF-to-myCAF ratios and a low OSR  
259 score showed the poorest outcome in low grade breast tumors, while patients with high iCAF-to-  
260 myCAF ratios and a high OSR score showed the best clinical outcome (Figure 6P). In high grade  
261 breast tumors, the OSR score does not appear to have a meaningful contribution to patient survival  
262 (Supplementary Figure 5O), indicating the importance of OSR in early steps of malignant  
263 progression. These results suggest that oxidative stress may be leveraged in low-grade tumors to  
264 increase the iCAF/myCAF ratio, thus improving the disease outcomes.

265

Lior et al, Figure 6



**Figure 6. NRF2 and the oxidative stress response contribute to the transition of normal fibroblasts to iCAF.** (A-E) Patient data from the TCGA breast cancer dataset was analyzed for cellular composition using the CIBERSORTx (Newman *et al*, 2015) algorithm and the results were ordered by the stress score. (F-O) Trajectory analysis. (F,K) UMAP plots of scRNA-seq data of breast (E) or pancreas (J) fibroblasts with data from normal samples, re-analyzed from publicly available datasets (Pal *et al*, 2021; Peng *et al*, 2019). (G,L) Clusters were annotated based on the stromal gene signatures we described in Supplementary Figure 3. (H,M) Trajectory analysis of breast and pancreas tumors and normal samples using the Monocle3 R toolkit. (I,N) Projections of the OSR score we previously defined. (J,O) Patient-level quantification of OSR scores. P-Values were calculated using one-way ANOVA, followed by Tukey's multiple comparisons test. (P) Kaplan-Meier analysis of overall survival for low-grade breast cancer patients from the METABRIC cohort (Curtis *et al*, 2012). Patients were stratified based on their OSR signature and iCAF/myCAF ratio, calculated by CIBERSORTx (median was used as cutoff). P-values were calculated from the log-rank test, and paired comparisons were calculated using the Survdiff function in R with FDR correction. (Q) Heatmap of the differentially expressed oxidative stress related genes from bulk RNA-seq between cell culture models of iCAFs, myCAFs and quiescent PSCs, re-analyzed from (Öhlund *et al*, 2017). Differentially expressed genes were filtered by a logFC threshold of 0.5 and adjusted p-value of 0.05. (R) Immortalized PSCs were seeded in matrigel for 3 days with either DMEM or KPC organoid conditioned medium (orgCM) and OSR genes *Hol* and *Sod3* were measured using qPCR. (S) Immortalized PSCs were seeded in 2D culture and were depleted of *Nrf2* using siRNA. Cells were then seeded in Matrigel for 3 days with orgCM, and known iCAF markers in this system *Clu* and *C3* were measured using qPCR. Results are shown as mean  $\pm$  SD. P-Values were calculated using two samples t-test.

267

268 **NRF2 plays a role in the transition of normal fibroblasts to iCAFs.**

269 Next, we used an established cell culture model of PDAC iCAFs and myCAFs (Öhlund *et al*, 2017)  
270 to investigate the role of NRF2 and oxidative stress in the function and plasticity of the CAFs.  
271 Ohlund *et al* utilized murine pancreas stellate cells (PSCs) that were grown as either myCAFs (2D  
272 culture), quiescent PSCs (3D culture with normal growth media) or iCAFs (3D culture with cancer  
273 organoid conditioned media (OrgCM) and sequenced cells under each condition to define unique  
274 genes upregulated in each population. Using this data, we assessed the expression levels of more  
275 than 400 oxidative stress related genes. The vast majority of differentially expressed OSR-related  
276 genes was upregulated in iCAFs and quiescent PSCs compared to myCAFs (Figure 6Q). A subset  
277 of these was upregulated in quiescent PSCs compared to iCAFs, while other genes were more  
278 highly expressed in iCAFs compared to PSCs (Figure 6Q). This apparent discrepancy from our  
279 trajectory analysis could be due to changes which the PSCs undergo in cell culture, causing them  
280 to somewhat lose their normal-like phenotype.

281 To experimentally validate these results, we cultured PSCs in quiescent- or iCAF-inducing  
282 conditions. We confirmed their quiescent-to-iCAF transition by monitoring the expression of the  
283 iCAF genes *Clu* and *C3*, as well as the myCAF gene *Acta2*. Indeed, the iCAF genes were  
284 upregulated and *Acta2* was downregulated in the growth conditions of iCAFs (3D with orgCM)  
285 (Supplementary Figure 5P-Q). Next, to check how OSR genes are expressed in iCAFs in this  
286 model, we checked the expression of known oxidative stress genes and NRF2 targets *Ho1* and  
287 *Sod3*. We found that both genes were upregulated in the iCAF growth conditions compared to  
288 quiescent PSCs, supporting the sequencing results (Figure 6R). Finally, we silenced *Nrf2* using  
289 siRNA prior to the addition of OrgCM to PSCs in 3D culture (Supplementary Figure 5R) and  
290 measured the expression of the iCAF markers *Clu* and *C3*. We found that silencing of *Nrf2* led to  
291 downregulation of *Clu* and *C3* (Figure 5S), suggesting that NRF2 is necessary for the quiescent-  
292 PSCs-to-iCAF transition.

293

294

## 295 **Discussion**

296 The tumor microenvironment (TME) is a complex network that consists not only of cancer cells  
297 but also a variety of other cellular players that dynamically interact with one another.  
298 Understanding the various stresses these cells undergo and the resulting cellular responses is  
299 essential for a holistic view of tumor biology and progression. Here we presented a comprehensive  
300 map of the network of stress responses in the TME, by dissecting five stress responses across four  
301 different tumor types. We found that the oxidative stress response and its central regulator NRF2  
302 play a role in the regulation of two stromal subpopulations - iCAFs and musclePer, and showed  
303 that low-grade breast patients with high OSR and high iCAF content exhibit better survival,  
304 suggesting a protective role for OSR and iCAF. Overall, our study offers an unbiased and holistic  
305 view of the stromal stress response landscape and proves the important contribution these cellular  
306 processes have on the tumor.

307 We observed a spatial relationship between the level of stress responses and proximity to the  
308 tumor, suggesting non-cell-autonomous signaling within the TME. This pattern may hint at the  
309 ability of cancer cells to induce stress responses in surrounding non-malignant cells. Not only does  
310 this finding highlight the prominent effect of cancer cells on their microenvironment, it also

311 emphasizes the dynamic interplay between cell types in the TME. This spatial gradient of stress  
312 responses could potentially be due to factors released by the cancer cells, such as cytokines, that  
313 act on the adjacent cells. This introduces the hypothesis that cancer cells may utilize these stress  
314 signals to subvert normal cell function for their benefit. For example, this gradient of stress signals  
315 could potentially influence immune cell function in the TME, enabling a more immune-  
316 suppressive and pro-tumorigenic environment (Salvagno *et al*, 2022). The spatial localization and  
317 functionality of immune cells were shown to be significantly influenced by metabolic stress (Chang  
318 *et al*, 2015). Thus, stress signals from cancer cells may serve to create an immunosuppressive  
319 microenvironment, further promoting tumor progression and resistance to therapy. Understanding  
320 the mechanisms behind this spatial gradient of stress responses could provide novel insights into  
321 tumor biology and how the cancer cells influence the non-malignant compartments of the TME.  
322 Our single-cell transcriptomic analysis revealed that while there is a certain level of universality  
323 in the stress response signatures across different tumor types, each tumor exhibits its unique  
324 pattern, suggesting an organ-specific regulation of these stress responses. This implies that stress  
325 responses in the TME are not merely reactive but could be intricate, dynamic, and tailored to the  
326 specific demands of each tumor. Whether this is driven by the mutational landscape or by organ  
327 dependencies remains to be determined and requires larger cohorts of patients. The unique stress  
328 response patterns we observed across different cell types highlight the diverse and adaptable nature  
329 of the tumor microenvironment. Endothelial cells, key components of the tumor vasculature,  
330 demonstrated the highest hypoxia score across all four tumor types. This is perhaps reflective of  
331 the poor vascularization often seen in solid tumors, which results in regions of low oxygen tension  
332 or hypoxia, a condition to which endothelial cells must adapt for survival and function (Abou  
333 Khouzam *et al*, 2021). B cells, crucial components of the adaptive immune response, exhibited the  
334 highest UPR across all tumors, possibly due to their inherent high antibody demand in response to  
335 the cancer cells (Downs-Canner *et al*, 2022). Unexpectedly, we found that immune cells, traditionally  
336 associated with immune surveillance and response, showed high levels of DDR, indicating a  
337 potential cell-non-autonomous role for the DDR (Dai *et al*, 2022). The OSR was found to be high  
338 in CAFs across all tumor types, emphasizing a potential role for the OSR in the fibroblasts. The  
339 oxidative stress experienced by these cells might contribute to their functions, including  
340 remodeling of the extracellular matrix and modulation of immune responses (Nguyen *et al*, 2018;

341 Chan *et al*, 2017; Nicolas *et al*, 2022; Giannoni *et al*, 2011). The variation in HSR activation,  
342 particularly its high expression in breast and pancreatic cancer cells, but not as much in ovarian  
343 and prostate tumors, may hint to specific physiological or molecular differences between these  
344 tumor types.

345 We found the OSR to play a significant role in the behavior of CAFs and pericytes, and our  
346 findings indicate that the transcription factor NRF2, a key regulator of OSR, may be instrumental  
347 in shaping the iCAF and musclePer phenotype. We showed that musclePer cells exhibit an elevated  
348 stress response, specifically HSR and OSR and are associated with smooth muscle contraction  
349 pathways. Their exact contribution to tumor dynamics is still unexplored, as is the role of the stress  
350 responses to their functionality. Regarding iCAFs, while an upregulation of OSR genes in iCAFs  
351 was shown before in PDAC(Elyada *et al*, 2019), the matter was not pursued. This is an intriguing  
352 link, considering the importance of the OSR and NRF2 in tumorigenesis and tumor progression.  
353 We observed higher levels of OSR in iCAFs compared to myCAF, hinting at a possible role of  
354 oxidative stress in driving the immune-regulatory phenotype of CAFs. This is further supported  
355 by the positive correlation between OSR and the iCAF signature across all analyzed tumor types.  
356 This suggests a potential role for the OSR in the development and function of iCAF, a notion that  
357 is supported by a study that demonstrated that loss of Cav1, a known regulator of NRF2, leads to  
358 mitochondrial dysfunction, oxidative stress, and aerobic glycolysis in CAFs and induces genomic  
359 instability in adjacent cancer cells (Nguyen *et al*, 2018). This further supports our suggestion that  
360 oxidative stress in CAFs can significantly impact the development and behavior of the tumor,  
361 hinting at a possible role of oxidative stress in driving the immune-regulatory phenotype of CAFs.  
362 Further investigation is necessary to elucidate the underlying mechanisms by which OSR affects  
363 the iCAF population and the transition of the TME towards a more anti-tumorigenic state.  
364

365 Toullec *et al*. showed in their study that oxidative stress can convert normal fibroblasts into (Toullec  
366 *et al*, 2010). In our study, using trajectory analysis, we found that CAFs transitioned from normal  
367 to iCAF and then to myCAF in two datasets of breast and pancreatic tumors, with a  
368 corresponding decrease in OSR along this trajectory. Understanding the mechanisms behind the  
369 effect of oxidative stress on fibroblasts transformations could provide valuable insights into how

370 to leverage this process for therapeutic benefits, particularly since iCAFs have been shown to  
371 attract immune cells and enable a more anti-tumorigenic environment, compared to myCAFs  
372 (Arpinati & Scherz-Shouval, 2023).

373 Our analysis of the TCGA datasets of breast, ovary and pancreas tumors demonstrated a correlation  
374 between a high OSR score and an enrichment of iCAFs, alongside a reduction in epithelial cells.  
375 This suggests the OSR might be integral not only to the rewiring of CAFs but also in modulating  
376 tumor progression. Our findings suggest that a higher OSR within the TME might not necessarily  
377 promote a pro-tumorigenic environment. Instead, an elevated OSR could potentially act as a  
378 restraining factor, potentially hindering tumor growth and progression (Arfin *et al*, 2021). In the  
379 early stages of tumor development, oxidative stress and other stress responses often act as a  
380 protective mechanism, aimed at maintaining cellular integrity and preventing malignant  
381 transformation. During this phase, elevated levels of reactive oxygen species (ROS) can promote  
382 apoptosis and senescence of precancerous cells, thus serving as a defense mechanism against  
383 tumorigenesis. However, as tumors progress, they can exploit these stress responses to their  
384 advantage. Chronic and unresolvable oxidative stress can result in a dysfunctional TME, leading  
385 to genomic instability, metabolic reprogramming, and immune evasion. At this point, oxidative  
386 stress becomes pro-tumorigenic, contributing to tumor growth, invasion, and resistance to  
387 therapies. This switch from a protective to a detrimental role reflects the dual-edged sword nature  
388 of oxidative stress in cancer, highlighting the complexity of the interplay between cellular stress  
389 responses and tumor progression. Our survival analysis of the breast cancer METABRIC cohort  
390 (Curtis *et al*, 2012) supports this claim: In patients with low-grade breast tumors, a high level of  
391 oxidative stress was correlated with a favorable prognosis, suggesting that at this stage, the tumor  
392 may still be susceptible to the cytotoxic effects of ROS. The ability of cancer cells to adapt and  
393 survive under high oxidative stress might be one of the critical steps in the transition from a low-  
394 grade to a high-grade tumor. In terms of therapeutic implications, our findings suggest the potential  
395 utility of antioxidant-based therapies for low-grade tumors. However, for high-grade tumors, the  
396 effectiveness of such therapies might be limited due to oxidative stress adaptation. Instead,  
397 alternative strategies could be explored.

398

399 Cancer progression and the complex interplay within the tumor microenvironment are largely  
400 influenced by a myriad of stress responses. Our extensive analysis of these stresses reveals not just  
401 the universality of these reactions, but the unique signatures each tumor type bears. As we have  
402 uncovered, the significance of NRF2, as a central player in the OSR, emerged strongly in our  
403 study, particularly in its association with iCAFs, suggesting a complex regulatory network that  
404 modulates the TME.

405

406

## 407 **Methods**

### 408 **Ethics statement**

409 All clinical samples and data were collected following approval by Memorial Sloan Kettering  
410 Cancer Center (MSKCC; IRB, protocol #15-149) and the Weizmann Institute of Science (IRB,  
411 protocols # 186-1) Institutional Review Boards.

412

### 413 **Human patient samples**

414 Human tumor microarrays (TMA) containing samples from patients were purchased from US  
415 Biomax Inc. (Figure 1: Breast - BR1503f, Pancreas - PA961f, Ovary - OV2084b, Prostate -  
416 PR807c. Figure 4: Breast - BR1191, Ovary - OV2001b, Prostate - PR1211) or assembled at  
417 MSKCC (Figure 4: Pancreas). The pancreas TMA (Figure 4) contains tumor samples from  
418 surgically resected primary pancreas ductal adenocarcinomas of patients treated at MSKCC;  
419 informed consent to study the tissue was obtained via MSK IRB protocol #15-149 and the  
420 Weizmann Institute of Science IRB, protocol # 186-1. FFPE whole tumor sections and deeply  
421 annotated demographic, clinical, pathologic and genomic (MSK-IMPACT<sup>TM</sup>) data were collected  
422 for all MSKCC patients in the study.

423

### 424 **Cell culture**

425 Mouse-immortalized PSCs and KPC organoids were kindly provided by David Tuveson's  
426 laboratory (CSHL, USA). PSCs were cultured in growth medium containing Dulbecco's modified  
427 Eagle's medium (DMEM; Biological industries, 01-052-1 A) supplemented with 10% fetal bovine  
428 serum (FBS) and 1% penicillin/streptomycin and were maintained at 37°C in 5% CO<sub>2</sub>. KPC

429 organoids were cultured in Corning® Matrigel® Growth Factor Reduced (GFR) Basement  
430 Membrane Matrix, Phenol Red-free, LDEV-free, (Corning, 365231) with complete organoid  
431 medium (Öhlund *et al*, 2017). Conditioned medium was collected following 3-4 days of culture with  
432 5% FBS DMEM. For 3D culture,  $4 \times 10^4$  PSCs were seeded in Matrigel® GFR in organoid  
433 conditioned media for 3 days, after which cells were harvested for further analysis.

434

#### 435 **RNA isolation and qPCR**

436 RNA isolation was performed using the Bio-Tri Reagent (Bio-Lab, cat. #959758027100),  
437 following the manufacturer's instructions. Complementary DNA (cDNA) synthesis was performed  
438 with High-Capacity RNA-to-cDNA Kit (Thermo Fisher Scientific, cat. #4387406). The primer  
439 sequences used for qPCR analysis are provided in Supplementary Table 4.

440

#### 441 **Immunofluorescent staining of the human tumor microarray**

442 Human tumor microarrays (TMA) containing samples from patients were purchased from US  
443 Biomax Inc. (Figure 1: Breast - BR1503f, Pancreas - PA961f, Ovary - OV2084b, Prostate -  
444 PR807c. Figure 4: Breast - BR1191, Ovary - OV2001b, Prostate - PR1211. Pancreas TMAs were  
445 generously given to us by Prof. David Kelsen, MSKCC; IRB, protocol #15-149). TMAs were  
446 deparaffinized and fixed with 10% neutral buffered formalin. Antigen retrieval was performed  
447 using citrate buffer (pH 6.0) or Tris-EDTA buffer (pH 9.0). Slides were then blocked with 10%  
448 BSA + 0.05% Tween20 and the antibodies were diluted in 2% BSA in 0.05% PBST and used in a  
449 multiplexed manner with OPAL reagents (Akoya Biosciences). All primary antibodies were  
450 incubated overnight at 4 °C. Briefly, following primary antibody incubation, slides were washed  
451 with 0.05% PBST, incubated with secondary antibodies conjugated to HRP, washed again, and  
452 incubated with OPAL reagents. Slides were then washed, and antigen retrieval was performed.  
453 Then, slides were washed with PBS and stained with the next primary antibody or with DAPI at  
454 the end of the cycle. Finally, slides were mounted using Immu-mount (#9990402, Thermo  
455 Scientific). Images were taken with a Pannoramic Scan II scanner,  $\times 20/0.8$  objective  
456 (3DHISTECH) or with a Phenocycler scanner (Akoya Biosciences). Images were analyzed using  
457 QuPath software (Bankhead *et al*, 2017). Cell segmentation was done using Cellpose (Stringer *et al*,  
458 2021). Distance analysis was performed using QuPath software. In Figure 1, cancer cells and  
459 immune cells were distinguished based on morphological parameters, using QuPath. For TFs -

460 positive staining was defined as nuclear staining. Antibodies used in this study are detailed in  
461 Supplementary Table 5.

462

#### 463 **scRNA-seq analysis**

464 The human single-cell RNA sequencing datasets used in this paper were analyzed using the Seurat  
465 (V4.3) pipeline (Stuart *et al*, 2019) in R v4.2.2. Cells were filtered with gene count between 200 and  
466 5000 (6000 for the pancreas data); total molecules count smaller than 20,000 (30,000 for the  
467 pancreas data); and a mitochondrial gene percentage less than 10% for the pancreas data, 20% for  
468 the breast and prostate data and 25% for the ovary data. Cells were normalized by the Sctransform  
469 V2 method. dimensionality reduction and clustering were done using default parameters. Cell  
470 types were defined by canonical markers. For breast, pancreas, and ovary – the different datasets  
471 were integrated using Seurat v4.3. For figures 1-3, normal samples were excluded from relevant  
472 data sets. Trajectory analysis was performed using Monocle3 (Trapnell *et al*, 2014) with default  
473 parameters.

474

475 Stress signatures were derived from gene ontology database (Ashburner *et al*, 2000). Each signature  
476 comprises between 47 and 231 genes and are listed in Supplementary Table 1. Expression of stress  
477 signature genes within each signature, across the various cell types in the different tumors, can be  
478 found in Supplementary Tables 7-10. Genes included were expressed in more than 30% of at least  
479 one cell type.

480

481 Different integration methods yield different clustering results. We acknowledge that while using  
482 Harmony integration (Korsunsky *et al*, 2019) on scRNA-seq data from Peng *et al* (Peng *et al*, 2019)  
483 led to the identification of a cluster of apCAFs (Shaashua *et al*, 2022). In this study we used Seurat  
484 integration(Stuart *et al*, 2019) and did not find this cluster.

485

#### 486 **Spatial transcriptomics analysis**

487 Publicly available count matrices were downloaded from 10x Genomics and processed using R  
488 v4.2.0 and Seurat v4.3. Data were normalized using SCTransform V2 method. Each spot was given  
489 a prediction score for the different cell types, using publicly available scRNA-seq data as

490 references (Pal *et al*, 2021; Chen *et al*, 2021a; Olbrecht *et al*, 2021; Geistlinger *et al*, 2021; Zhang *et al*,  
491 2022). Analysis was performed using default parameters.

492

### 493 **CIBERSORTx**

494 To estimate the fraction of the different cell types in the TCGA datasets, we used the computational  
495 deconvolution tool, CIBERSORTx, that estimates the relative abundance of individual cell types  
496 in a mixed cell population based on single cell RNA-seq profiles (Newman *et al*, 2015).  
497 CIBERSORTx results are detailed in Supplementary Table 6.

498

### 499 **Survival Analysis**

500 Data was obtained from the METABRIC dataset (Curtis *et al*, 2012). Patients with missing  
501 information about tumor grade/stage were removed, as well as patients treated with chemotherapy.  
502 Patients were then stratified based on their iCAF/myCAF ratios, which were calculated by  
503 CIBERSORTx (see above), and based on the OSR scores. Kaplan Meier (KM) analysis of overall  
504 survival with log rank p value was performed on patients stratified by median expression of each  
505 of these signatures.

506

### 507 **Statistical analysis**

508 Statistical analysis and visualization were performed using R 4.2.2, and Prism 9.2.0 (Graphpad,  
509 USA). Statistical tests were performed as described in each Figure legend. \* p < 0.05, \*\* p < 0.005,  
510 \*\*\* p < 0.0005.

511

### 512 **References**

513 Abou Khouzam R, Brodaczewska K, Filipiak A, Zeinelabdin NA, Buart S, Szczylik C, Kieda C &  
514 Chouaib S (2021) Tumor Hypoxia Regulates Immune Escape/Invasion: Influence on  
515 Angiogenesis and Potential Impact of Hypoxic Biomarkers on Cancer Therapies. *Front  
516 Immunol* 11

517 Akman M, Belisario DC, Salaroglio IC, Kopecka J, Donadelli M, De Smaele E & Riganti C (2021)  
518 Hypoxia, endoplasmic reticulum stress and chemoresistance: dangerous liaisons. *Journal of  
519 Experimental and Clinical Cancer Research* 40 doi:10.1186/s13046-020-01824-3  
520 [PREPRINT]

521 Arfin S, Jha NK, Jha SK, Kesari KK, Ruokolainen J, Roychoudhury S, Rathi B & Kumar D (2021)  
522 Oxidative stress in cancer cell metabolism. *Antioxidants* 10 doi:10.3390/antiox10050642  
523 [PREPRINT]  
524 Armulik A, Genové G & Betsholtz C (2011) Pericytes: Developmental, Physiological, and  
525 Pathological Perspectives, Problems, and Promises. *Dev Cell* 21: 193–215  
526 Arpinati L & Scherz-Shouval R (2023) From gatekeepers to providers: regulation of immune  
527 functions by cancer-associated fibroblasts. *Trends Cancer*  
528 Ashburner M, Ball CA, Blake JA, Botstein D, Butler H, Cherry JM, Davis AP, Dolinski K, Dwight  
529 SS, Eppig JT, et al (2000) Gene ontology: Tool for the unification of biology. *Nat Genet* 25:  
530 25–29 doi:10.1038/75556 [PREPRINT]  
531 Bankhead P, Loughrey MB, Fernández JA, Dombrowski Y, McArt DG, Dunne PD, McQuaid S,  
532 Gray RT, Murray LJ, Coleman HG, et al (2017) QuPath: Open source software for digital  
533 pathology image analysis. *Sci Rep* 7: 16878  
534 Bedeschi M, Marino N, Cavassi E, Piccinini F & Tesei A (2023) Cancer-Associated Fibroblast:  
535 Role in Prostate Cancer Progression to Metastatic Disease and Therapeutic Resistance. *Cells*  
536 12: 802  
537 Bonollo F, Thalmann GN, Kruithof-de Julio M & Karkampouna S (2020) The Role of Cancer-  
538 Associated Fibroblasts in Prostate Cancer Tumorigenesis. *Cancers (Basel)* 12: 1887  
539 Chan JSK, Tan MJ, Sng MK, Teo Z, Phua T, Choo CC, Li L, Zhu P & Tan NS (2017) Cancer-  
540 associated fibroblasts enact field cancerization by promoting extratumoral oxidative stress.  
541 *Cell Death Dis* 8  
542 Chang C-H, Qiu J, O'Sullivan D, Buck MD, Noguchi T, Curtis JD, Chen Q, Gindin M, Gubin MM,  
543 van der Windt GJW, et al (2015) Metabolic Competition in the Tumor Microenvironment Is a  
544 Driver of Cancer Progression. *Cell* 162: 1229–1241  
545 Chen M & Xie S (2018) Therapeutic targeting of cellular stress responses in cancer. *Thorac Cancer*  
546 9: 1575–1582  
547 Chen S, Zhu G, Yang Y, Wang F, Xiao YT, Zhang N, Bian X, Zhu Y, Yu Y, Liu F, et al (2021a)  
548 Single-cell analysis reveals transcriptomic remodellings in distinct cell types that contribute to  
549 human prostate cancer progression. *Nat Cell Biol* 23: 87–98  
550 Chen X & Cubillos-Ruiz JR (2021) Endoplasmic reticulum stress signals in the tumour and its  
551 microenvironment. *Nat Rev Cancer* 21: 71–88 doi:10.1038/s41568-020-00312-2 [PREPRINT]  
552 Chen Y, McAndrews KM & Kalluri R (2021b) Clinical and therapeutic relevance of cancer-  
553 associated fibroblasts. *Nat Rev Clin Oncol* 18: 792–804 doi:10.1038/s41571-021-00546-5  
554 [PREPRINT]  
555 Curtis C, Shah SP, Chin S-F, Turashvili G, Rueda OM, Dunning MJ, Speed D, Lynch AG,  
556 Samarajiwa S, Yuan Y, et al (2012) The genomic and transcriptomic architecture of 2,000  
557 breast tumours reveals novel subgroups. *Nature* 486: 346–352  
558 Cyran AM & Zhitkovich A (2022) Heat Shock Proteins and HSF1 in Cancer. *Front Oncol* 12  
559 doi:10.3389/fonc.2022.860320 [PREPRINT]  
560 Dai Z, Zhang W, Shang M, Tang H, Wu L, Wu Y, Wang T & Bian P (2022) A Non-Cell-  
561 Autonomous Mode of DNA Damage Response in Soma of *Caenorhabditis elegans*. *Int J Mol  
562 Sci* 23: 7544  
563 Downs-Canner SM, Meier J, Vincent BG & Serody JS (2022) B Cell Function in the Tumor  
564 Microenvironment. *Annu Rev Immunol* 40: 169–193

565 Elyada E, Bolisetty M, Laise P, Flynn WF, Courtois ET, Burkhardt RA, Teinor JA, Belleau P, Biffi  
566 G, Lucito MS, *et al* (2019) Cross-Species Single-Cell Analysis of Pancreatic Ductal  
567 Adenocarcinoma Reveals Antigen-Presenting Cancer-Associated Fibroblasts. *Cancer Discov*  
568 9: 1102–1123

569 Ganguly D, Chandra R, Karalis J, Teke M, Aguilera T, Maddipati R, Wachsmann MB, Ghersi D,  
570 Siravegna G, Zeh HJ, *et al* (2020) Cancer-associated fibroblasts: Versatile players in the tumor  
571 microenvironment. *Cancers (Basel)* 12: 1–35 doi:10.3390/cancers12092652 [PREPRINT]

572 Geistlinger L, Oh S, Ramos M, Schiffer L, LaRue RS, Henzler CM, Munro SA, Daughters C,  
573 Nelson AC, Winterhoff BJ, *et al* (2021) Multiomic analysis of subtype evolution and  
574 heterogeneity in high-grade serous ovarian carcinoma. *Cancer Res* 80: 4335–4345

575 Giannoni E, Bianchini F, Calorini L & Chiarugi P (2011) Cancer Associated Fibroblasts Exploit  
576 Reactive Oxygen Species Through a Proinflammatory Signature Leading to Epithelial  
577 Mesenchymal Transition and Stemness. *Antioxid Redox Signal* 14: 2361–2371

578 Grunberg N, Levi-Galibov O & Scherz-Shouval R (2020) The Role of HSF1 and the Chaperone  
579 Network in the Tumor Microenvironment. In *HSF1 and Molecular Chaperones in Biology and*  
580 *Cancer*, Mendillo ML Pincus D & Scherz-Shouval R (eds) pp 101–111. Cham: Springer  
581 International Publishing

582 Grunberg N, Pevsner-Fischer M, Goshen-Lago T, Diment J, Stein Y, Lavon H, Mayer S, Levi-  
583 Galibov O, Friedman G, Ofir-Birin Y, *et al* (2021) Cancer-associated fibroblasts promote  
584 aggressive gastric cancer phenotypes via heat shock factor 1-mediated secretion of  
585 extracellular vesicles. *Cancer Res*

586 Hetz C (2012) The unfolded protein response: Controlling cell fate decisions under ER stress and  
587 beyond. *Nat Rev Mol Cell Biol* 13: 89–102

588 Houthuijzen JM, de Bruijn R, van der Burg E, Drenth AP, Wientjens E, Filipovic T, Bullock E,  
589 Brambillasca CS, Pulver EM, Nieuwland M, *et al* (2023) CD26-negative and CD26-positive  
590 tissue-resident fibroblasts contribute to functionally distinct CAF subpopulations in breast  
591 cancer. *Nat Commun* 14: 183

592 Jiang Y, Tao Z, Chen H & Xia S (2021) Endoplasmic Reticulum Quality Control in Immune Cells.  
593 *Front Cell Dev Biol* 9 doi:10.3389/fcell.2021.740653 [PREPRINT]

594 Khariaishvili G, Simkova D, Bouchalova K, Gachechiladze M, Narsia N & Bouchal J (2014) The  
595 role of cancer-associated fibroblasts, solid stress and other microenvironmental factors in  
596 tumor progression and therapy resistance. *Cancer Cell Int* 14 doi:10.1186/1475-2867-14-41  
597 [PREPRINT]

598 Korsunsky I, Millard N, Fan J, Slowikowski K, Zhang F, Wei K, Baglaenko Y, Brenner M, Loh P &  
599 Raychaudhuri S (2019) Fast, sensitive and accurate integration of single-cell data with  
600 Harmony. *Nat Methods* 16: 1289–1296

601 Krock BL, Skuli N & Simon MC (2011) Hypoxia-Induced Angiogenesis: Good and Evil. *Genes*  
602 *Cancer* 2: 1117–1133

603 Lavie D, Ben-Shmuel A, Erez N & Scherz-Shouval R (2022) Cancer-associated fibroblasts in the  
604 single-cell era. *Nat Cancer* 3: 793–807 doi:10.1038/s43018-022-00411-z [PREPRINT]

605 Leprivier G, Rotblat B, Khan D, Jan E & Sorensen PH (2015) Stress-mediated translational control  
606 in cancer cells. *Biochim Biophys Acta Gene Regul Mech* 1849: 845–860  
607 doi:10.1016/j.bbagr.2014.11.002 [PREPRINT]

608 Levi-Galibov O, Lavon H, Wassermann-Dozorets R, Pevsner-Fischer M, Mayer S, Wershof E, Stein  
609 Y, Brown LE, Zhang W, Friedman G, *et al* (2020) Heat Shock Factor 1-dependent  
610 extracellular matrix remodeling mediates the transition from chronic intestinal inflammation to  
611 colon cancer. *Nat Commun* 11

612 Li X, Pan J, Liu T, Yin W, Miao Q, Zhao Z, Gao Y, Zheng W, Li H, Deng R, *et al* (2023) Novel  
613  $TCF21^{high}$  pericyte subpopulation promotes colorectal cancer metastasis by remodelling  
614 perivascular matrix. *Gut* 72: 710–721

615 Li X, Zhang K & Li Z (2011) Unfolded protein response in cancer: The Physician's perspective. *J  
616 Hematol Oncol* 4 doi:10.1186/1756-8722-4-8 [PREPRINT]

617 Li Y, Zhao L & Li XF (2021) Hypoxia and the Tumor Microenvironment. *Technol Cancer Res  
618 Treat* 20 doi:10.1177/15330338211036304 [PREPRINT]

619 Liu T, Han C, Wang S, Fang P, Ma Z, Xu L & Yin R (2019) Cancer-associated fibroblasts: An  
620 emerging target of anti-cancer immunotherapy. *J Hematol Oncol* 12 doi:10.1186/s13045-019-  
621 0770-1 [PREPRINT]

622 Lord CJ & Ashworth A (2012) The DNA damage response and cancer therapy. *Nature* 481: 287–  
623 294 doi:10.1038/nature10760 [PREPRINT]

624 Lyle LT, Lockman PR, Adkins CE, Mohammad AS, Sechrest E, Hua E, Palmieri D, Liewehr DJ,  
625 Steinberg SM, Kloc W, *et al* (2016) Alterations in Pericyte Subpopulations Are Associated  
626 with Elevated Blood–Tumor Barrier Permeability in Experimental Brain Metastasis of Breast  
627 Cancer. *Clinical Cancer Research* 22: 5287–5299

628 Madden E, Logue SE, Healy SJ, Manie S & Samali A (2019) The role of the unfolded protein  
629 response in cancer progression: From oncogenesis to chemoresistance. *Biol Cell* 111: 1–17  
630 doi:10.1111/boc.201800050 [PREPRINT]

631 Martinez-Outschoorn UE, Balliet RM, Rivadeneira DB, Chiavarina B, Pavlides S, Wang C,  
632 Whitaker-Menezes D, Daumer KM, Lin Z, Witkiewicz AK, *et al* (2010) Oxidative stress in  
633 cancer associated fibroblasts drives tumor-stroma co-evolution: A new paradigm for  
634 understanding tumor metabolism, the field effect and genomic instability in cancer cells. *Cell  
635 Cycle* 9: 3256–3276

636 Matsuzaki S, Hiratsuka T, Taniguchi M, Shingaki K, Kubo T, Kiya K, Fujiwara T, Kanazawa S,  
637 Kanematsu R, Maeda T, *et al* (2015) Physiological ER stress mediates the differentiation of  
638 fibroblasts. *PLoS One* 10

639 Miles J, Scherz-Shouval R & van Oosten-Hawle P (2019) Expanding the Organismal Proteostasis  
640 Network: Linking Systemic Stress Signaling with the Innate Immune Response. *Trends  
641 Biochem Sci* 44: 927–942 doi:10.1016/j.tibs.2019.06.009 [PREPRINT]

642 Mogi K, Yoshihara M, Iyoshi S, Kitami K, Uno K, Tano S, Koya Y, Sugiyama M, Yamakita Y,  
643 Nawa A, *et al* (2021) Ovarian Cancer-Associated Mesothelial Cells: Transdifferentiation to  
644 Minions of Cancer and Orchestrate Developing Peritoneal Dissemination. *Cancers (Basel)* 13:  
645 1352

646 Mun JY, Leem SH, Lee JH & Kim HS (2022) Dual Relationship Between Stromal Cells and  
647 Immune Cells in the Tumor Microenvironment. *Front Immunol* 13  
648 doi:10.3389/fimmu.2022.864739 [PREPRINT]

649 Newman AM, Liu CL, Green MR, Gentles AJ, Feng W, Xu Y, Hoang CD, Diehn M & Alizadeh  
650 AA (2015) Robust enumeration of cell subsets from tissue expression profiles. *Nat Methods*  
651 12: 453–457

652 Nguyen HG, Conn CS, Kye Y, Xue L, Forester CM, Cowan JE, Hsieh AC, Cunningham JT, Truillet  
653 C, Tameire F, *et al* (2018) Development of a stress response therapy targeting aggressive  
654 prostate cancer

655 Nicolas AM, Pesic M, Engel E, Ziegler PK, Diefenhardt M, Kennel KB, Buettner F, Conche C,  
656 Petrocelli V, Elwakeel E, *et al* (2022) Inflammatory fibroblasts mediate resistance to  
657 neoadjuvant therapy in rectal cancer. *Cancer Cell* 40: 168-184.e13

658 Öhlund D, Handly-Santana A, Biffi G, Elyada E, Almeida AS, Ponz-Sarvise M, Corbo V, Oni TE,  
659 Hearn SA, Lee EJ, *et al* (2017) Distinct populations of inflammatory fibroblasts and  
660 myofibroblasts in pancreatic cancer. *J Exp Med* 214: 579-596

661 Olbrecht S, Busschaert P, Qian J, Vanderstichele A, Loverix L, Van Gorp T, Van Nieuwenhuysen  
662 E, Han S, Van den Broeck A, Coosemans A, *et al* (2021) High-grade serous tubo-ovarian  
663 cancer refined with single-cell RNA sequencing: specific cell subtypes influence survival and  
664 determine molecular subtype classification. *Genome Med* 13: 111

665 Pal B, Chen Y, Vaillant F, Capaldo BD, Joyce R, Song X, Bryant VL, Penington JS, Di Stefano L,  
666 Tubau Ribera N, *et al* (2021) A single-cell RNA expression atlas of normal, preneoplastic and  
667 tumorigenic states in the human breast. *EMBO J* 40: e107333

668 Peng J, Sun BF, Chen CY, Zhou JY, Chen YS, Chen H, Liu L, Huang D, Jiang J, Cui GS, *et al*  
669 (2019) Single-cell RNA-seq highlights intra-tumoral heterogeneity and malignant progression  
670 in pancreatic ductal adenocarcinoma. *Cell Res* 29: 725-738

671 Ping Q, Yan R, Cheng X, Wang W, Zhong Y, Hou Z, Shi Y, Wang C & Li R (2021) Cancer-  
672 associated fibroblasts: overview, progress, challenges, and directions. *Cancer Gene Ther* 28:  
673 984-999 doi:10.1038/s41417-021-00318-4 [PREPRINT]

674 Ramirez MU, Hernandez SR, Soto-Pantoja DR & Cook KL (2020) Endoplasmic reticulum stress  
675 pathway, the unfolded protein response, modulates immune function in the tumor  
676 microenvironment to impact tumor progression and therapeutic response. *Int J Mol Sci* 21  
677 doi:10.3390/ijms21010169 [PREPRINT]

678 Richter K, Haslbeck M & Buchner J (2010) The Heat Shock Response: Life on the Verge of Death.  
679 *Mol Cell* 40: 253-266 doi:10.1016/j.molcel.2010.10.006 [PREPRINT]

680 Roy R, Chun J & Powell SN (2012) BRCA1 and BRCA2: Different roles in a common pathway of  
681 genome protection. *Nat Rev Cancer* 12: 68-78 doi:10.1038/nrc3181 [PREPRINT]

682 Sahai E, Astsaturov I, Cukierman E, DeNardo DG, Egeblad M, Evans RM, Fearon D, Greten FR,  
683 Hingorani SR, Hunter T, *et al* (2020) A framework for advancing our understanding of cancer-  
684 associated fibroblasts. *Nat Rev Cancer* 20: 174-186 doi:10.1038/s41568-019-0238-1  
685 [PREPRINT]

686 Salvagno C, Mandula JK, Rodriguez PC & Cubillos-Ruiz JR (2022) Decoding endoplasmic  
687 reticulum stress signals in cancer cells and antitumor immunity. *Trends Cancer* 8: 930-943  
688 doi:10.1016/j.trecan.2022.06.006 [PREPRINT]

689 Santi A, Kugeratski FG & Zanivan S (2018) Cancer Associated Fibroblasts: The Architects of  
690 Stroma Remodeling. *Proteomics* 18: 1-15

691 Scherz-Shouval R, Santagata S, Mendillo ML, Sholl LM, Ben-Aharon I, Beck AH, Dias-Santagata  
692 D, Koeva M, Stemmer SM, Whitesell L, *et al* (2014) The reprogramming of tumor stroma by  
693 HSF1 is a potent enabler of malignancy. *Cell* 158: 564-578

694 Sebestyén A, Kopper L, Dankó T & Tímár J (2021) Hypoxia Signaling in Cancer: From Basics to  
695 Clinical Practice. *Pathology and Oncology Research* 27 doi:10.3389/pore.2021.1609802  
696 [PREPRINT]

697 Seebacher NA, Krchniakova M, Stacy AE, Skoda J & Jansson PJ (2021) Tumour microenvironment  
698 stress promotes the development of drug resistance. *Antioxidants* 10  
699 doi:10.3390/antiox10111801 [PREPRINT]

700 Semenza GL (2014) Oxygen Sensing, Hypoxia-Inducible Factors, and Disease Pathophysiology.  
701 *Annual Review of Pathology: Mechanisms of Disease* 9: 47–71

702 Shaashua L, Ben-Shmuel A, Pevsner-Fischer M, Friedman G, Levi-Galibov O, Nandakumar S,  
703 Barki D, Nevo R, Brown LE, Zhang W, *et al* (2022) BRCA mutational status shapes the  
704 stromal microenvironment of pancreatic cancer linking clusterin expression in cancer  
705 associated fibroblasts with HSF1 signaling. *Nat Commun* 13: 6513

706 Sies H & Jones DP (2020) Reactive oxygen species (ROS) as pleiotropic physiological signalling  
707 agents. *Nat Rev Mol Cell Biol* 21: 363–383

708 Siwecka N, Rozpędek W, Pytel D, Wawrzynkiewicz A, Dziki A, Dziki Ł, Alan Diehl J & Majsterek  
709 I (2019) Dual role of endoplasmic reticulum stress-mediated unfolded protein response  
710 signaling pathway in carcinogenesis. *Int J Mol Sci* 20 doi:10.3390/ijms20184354 [PREPRINT]

711 Steele NG, Carpenter ES, Kemp SB, Sirihorachai VR, The S, Delrosario L, Lazarus J, Amir E ad D,  
712 Gunchick V, Espinoza C, *et al* (2020) Multimodal mapping of the tumor and peripheral blood  
713 immune landscape in human pancreatic cancer. *Nat Cancer* 1: 1097–1112

714 Stringer C, Wang T, Michaelos M & Pachitariu M (2021) Cellpose: a generalist algorithm for  
715 cellular segmentation. *Nat Methods* 18: 100–106

716 Stuart T, Butler A, Hoffman P, Hafemeister C, Papalexi E, Mauck III WM, Hao Y, Stoeckius M,  
717 Smibert P & Satija R (2019) Comprehensive Integration of Single-Cell Data. *Cell* 177: 1888–  
718 1902.e21

719 Sun R, Kong X, Qiu X, Huang C & Wong PP (2021) The Emerging Roles of Pericytes in  
720 Modulating Tumor Microenvironment. *Front Cell Dev Biol* 9 doi:10.3389/fcell.2021.676342  
721 [PREPRINT]

722 Toullec A, Gerald D, Despouy G, Bourachot B, Cardon M, Lefort S, Richardson M, Rigaill G,  
723 Parrini MC, Lucchesi C, *et al* (2010) Oxidative stress promotes myofibroblast differentiation  
724 and tumour spreading. *EMBO Mol Med* 2: 211–230

725 Trapnell C, Cacchiarelli D, Grimsby J, Pokharel P, Li S, Morse M, Lennon NJ, Livak KJ, Mikkelsen  
726 TS & Rinn JL (2014) The dynamics and regulators of cell fate decisions are revealed by  
727 pseudotemporal ordering of single cells. *Nat Biotechnol* 32: 381–386

728 Varone E, Decio A, Chernorudskiy A, Minoli L, Brunelli L, Ioli F, Piotti A, Pastorelli R, Fratelli M,  
729 Gobbi M, *et al* (2021) The ER stress response mediator ERO1 triggers cancer metastasis by  
730 favoring the angiogenic switch in hypoxic conditions. *Oncogene* 40: 1721–1736

731 Verginadis II, Avgousti H, Monslow J, Skoufos G, Chinga F, Kim K, Leli NM, Karagounis I V.,  
732 Bell BI, Velalopoulou A, *et al* (2022) A stromal Integrated Stress Response activates  
733 perivascular cancer-associated fibroblasts to drive angiogenesis and tumour progression. *Nat  
734 Cell Biol* 24: 940–953

735 Werba G, Weissinger D, Kawaler EA, Zhao E, Kalfakakou D, Dhara S, Wang L, Lim HB, Oh G,  
736 Jing X, *et al* (2023) Single-cell RNA sequencing reveals the effects of chemotherapy on  
737 human pancreatic adenocarcinoma and its tumor microenvironment. *Nat Commun* 14: 797

738 Wu SZ, Al-Eryani G, Roden DL, Junankar S, Harvey K, Andersson A, Thennavan A, Wang C,  
739 Torpy JR, Bartonicek N, *et al* (2021) A single-cell and spatially resolved atlas of human breast  
740 cancers. *Nat Genet* 53: 1334–1347

741 Zhang K, Pekcan Erkan E, Jamalzadeh S, Dai J, Andersson N, Kaipio K, Lamminen T, Mansuri N,  
742 Huhtinen K, Carpén O, *et al* (2022) Longitudinal single-cell RNA-seq analysis reveals stress-  
743 promoted chemoresistance in metastatic ovarian cancer


744 Zhang L, Fok JJL, Mirabella F, Aronson LI, Fryer RA, Workman P, Morgan GJ & Davies FE  
745 (2013) Hsp70 inhibition induces myeloma cell death via the intracellular accumulation of  
746 immunoglobulin and the generation of proteotoxic stress. *Cancer Lett* 339: 49–59

747

748

749 **Supplementary Figures**


Lior et al, Supplementary Figure 1



**Supplementary Figure 1. scRNA-seq data analysis uncovers shared and unique stress response activation patterns across different tumors.** (A-E) scRNA-seq data from human tumors was reanalyzed using the Seurat R toolkit. Stress signatures (Supplementary Table 1) were projected on scRNA UMAP plots. (A) OSR; (B) HySR; (C) HSR; (D) UPR; and (E) DDR.


750

Lior et al, Supplementary Figure 2




**Supplementary Figure 2. Spatial transcriptomic analysis confirms enrichment of the oxidative stress signature in CAFs.** (A-B) Publicly available human cancer slides from the 10X genomic website ([www.10xgenomics.com/resources/datasets](http://www.10xgenomics.com/resources/datasets)) were re-analyzed using the Seurat R toolkit. Slides from 3 breast, 2 ovarian, and 3 prostate tumors were analyzed. A slide from one breast cancer patient is presented. Using our analysis of scRNA-seq data we deconvoluted the Visium spatial transcriptomic data to predict cell type distribution in each Visium spot (A). The stress signatures we defined were projected on the spatial transcriptomics data (B). (C-E) Quantification of each tumor type. Per patient, we defined each Visium spot as expression either low or high stress for each of the stress responses (stratification based on mean), and then averaged the predicted percentage of the various cell types. (C) - breast, (D) - ovary, (E) - prostate. P Values were calculated using Chi-test.

Lior et al, Supplementary Figure 3




**Supplementary Figure 3. Cancer-associated pericytes are composed of two distinct subpopulations.** Pan-cancer fibroblast and pericyte subpopulation signatures were defined using differential gene expression analysis of the four datasets. **(A-E)** Signature projections of the subtype signatures, which are presented in Supplementary Table 2. **(F)** Pathway analysis of two distinct cancer associated pericyte subpopulations.

Lior et al, Supplementary Figure 4



**Supplementary Figure 4. scRNA-seq analysis highlights distinctive activation of hypoxia and oxidative stress responses in various subpopulations of the tumor non-immune stromal cells.** Single-cell RNA-seq data from human tumors was reanalyzed using the Seurat R toolkit. Quantification of stress scores in the different fibroblast (A-E) and pericyte (F-J) subpopulations of each tumor type, as presented in Figure 4. (A,J) OSR; (B,G) HySR; (C,H) HSR; (D,I) UPR; and (E,J) DDR. P-Values were calculated using the paired two-sided Student t-test.

Lior et al, Supplementary Figure 5



755

**Supplementary Figure 5. The relative amount of epithelial cells is negatively correlated with OSR and HySR scores in pancreas and ovary tumors. (A-B)** Pearson correlation coefficients between stress and cell type scores in breast and pancreas tumors, calculated from the scRNA-seq data. **A** - myCAF<sub>s</sub>; **B** – matriPer. P-Values were calculated using one sample t-test ( $\mu=0$ ). **(C-L)** Patient data from the TCGA pancreas (**C-G**) and ovary (**H-L**) cancer datasets were analyzed for cellular composition using the CIBERSORTx (Newman *et al*, 2015) algorithm and the results were ordered by the stress score. **(M-N)** patient-level quantification of stress scores of breast (**D**) and pancreas (**E**) tumors, calculated from scRNA-seq data of normal and tumor samples (Pal *et al*, 2021; Peng *et al*, 2019). P-Values were calculated using one-way ANOVA, followed by Tukey's multiple comparisons test. **(P)** Kaplan-Meier curves of overall survival for high-grade breast cancer patients from the METABRIC cohort (Curtis *et al*, 2012). Patients were stratified based on their OSR signature and iCAF/myCAF ratio, calculated by CIBERSORTx (median was used as cutoff). P-values were calculated from the log-rank test and paired comparisons were calculated using the Survdiff function in R with FDR correction. **(P)** Immortalized PSCs were seeded in matrigel for 3 days with either DMEM or KPC organoid conditioned medium (orgCM) and iCAF (**P**) and myCAF (**Q**) genes were measured using qPCR. **(R)** Immortalized PSCs were seeded in 2D culture and were depleted of *Nrf2* using siRNA, and knockdown was measured using qPCR. Results are shown as mean  $\pm$  SD. P-Values were calculated using two samples t-test.